On August 11, A-share pharmaceutical leader Gan Li Pharmaceutical reversed the market. As of 9:40, it reported 74.47 yuan/share, with a closed capital of 935 million yuan. The reason behind the stock price change may be due to a major overseas licensing cooperation announcement disclosed by the company the night before. On the evening of August 10, Ganli Pharmaceutical issued an announcement stating that the company reached an exclusive license agreement with international pharmaceutical giant A. usenarini International Licensing S.A., granting it the right to market, register and commercialize boflavin in 39 European countries and regions, including 27 European countries and the United Kingdom. In response to the company's stock price rise and stop today and the details of the above cooperation, the reporter called Ganli Pharmaceutical Securities Department as an investor. The wiring staff responded that the company is unaware of changes in the secondary market, but the company issued a relevant overseas order announcement yesterday. It is expected that the order will have a certain impact on the company's profit this year, but the details still depend on the implementation of the agreement. The company's net profit target for 2026 is 1.43 billion yuan, and it is currently working towards the target. The specific results are subject to subsequent announcements. Looking back at Gan Li Pharmaceutical's recent performance trend, phased pressure is already evident. In response, the staff mentioned above explained that the decline in performance in the first quarter was caused by a combination of factors: in terms of product structure, the “Mendong” series, which had higher sales, was underpriced, which had a certain impact on the overall profit level; on the production side, the company's Beijing factory area and Shandong factory were switching, which had a certain impact on production capacity in the process. In addition, the tax rate adjustment after the year also had some impact on the company's performance.

On August 11, A-share pharmaceutical leader Gan Li Pharmaceutical reversed the market. As of 9:40, it reported 74.47 yuan/share, with a closed capital of 935 million yuan. The reason behind the stock price change may be due to a major overseas licensing cooperation announcement disclosed by the company the night before. On the evening of August 10, Ganli Pharmaceutical issued an announcement stating that the company reached an exclusive license agreement with international pharmaceutical giant A. usenarini International Licensing S.A., granting it the right to market, register and commercialize boflavin in 39 European countries and regions, including 27 European countries and the United Kingdom. In response to the company's stock price rise and stop today and the details of the above cooperation, the reporter called Ganli Pharmaceutical Securities Department as an investor. The wiring staff responded that the company is unaware of changes in the secondary market, but the company issued a relevant overseas order announcement yesterday. It is expected that the order will have a certain impact on the company's profit this year, but the details still depend on the implementation of the agreement. The company's net profit target for 2026 is 1.43 billion yuan, and it is currently working towards the target. The specific results are subject to subsequent announcements. Looking back at Gan Li Pharmaceutical's recent performance trend, phased pressure is already evident. In response, the staff mentioned above explained that the decline in performance in the first quarter was caused by a combination of factors: in terms of product structure, the “Mendong” series, which had higher sales, was underpriced, which had a certain impact on the overall profit level; on the production side, the company's Beijing factory area and Shandong factory were switching, which had a certain impact on production capacity in the process. In addition, the tax rate adjustment after the year also had some impact on the company's performance.